Available on Amazon, iHerb, Walmart, and health food stores
Yu et al., 2012)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Tria
Evidence signal Provider-reviewed bundle 8 source-backed citations are connected to this page
The unprecedented demand for prescription drugs, specifically GLP-1 receptor agonists (GLP-1s), for type 2 diabetes and obesity has gained significant attention
In order to improve the medication compliance of diabetic patients, polylactic-co-glycolic acid (PLGA) was used to wrap exenatide drug, which has sustained-release effect, and the half-life is as long as 5-6 days